Metastatic Spine Disease

Metastatic spine disease is the most common neoplasm of the spine, representing 90% of all spinal tumors. It significantly impacts quality of life through pain, neurological dysfunction, and mechanical instability.

Epidemiology:

• 10-30% of cancer patients develop spinal metastases
• Spine is the most common site of skeletal metastasis (Batson's plexus)
• Thoracic spine most common (70%), followed by lumbar (20%), cervical (10%)
• 5-10% of metastatic spine patients develop MESCC
• Breast, prostate, lung, thyroid, kidney (BPLTK) = 80% of cases

Distribution by Level:

Anatomical Pattern of Involvement:

• Vertebral body: 85% of lesions (anterior column)
• Pedicles: 60% involvement
• Posterior elements: 40% involvement
• Isolated posterior elements: Under 5%

Metastatic Cascade

The metastatic process to spine involves:

1. Local invasion - Primary tumor invades local vasculature
2. Intravasation - Tumor cells enter circulation
3. Survival - Evade immune surveillance in bloodstream
4. Extravasation - Exit at distant sites (Batson's plexus key role)
5. Colonization - Establish micrometastasis in marrow
6. Angiogenesis - Develop blood supply for growth

Bone Lesion Types

Primary Tumor Characteristics

SINS - Spinal Instability Neoplastic Score

SINS Score Components (Maximum 18 points):

SINS Interpretation:

• 0-6: Stable - no surgical consultation required
• 7-12: Potentially unstable - surgical consultation recommended
• 13-18: Unstable - surgical stabilization required

Bilsky Epidural Compression Scale

View larger

NOMS Decision Framework

History

Physical Examination

MESCC - Oncological Emergency

Metastatic Epidural Spinal Cord Compression:

• 5-10% of cancer patients develop MESCC
• Neurological deterioration can be rapid (hours to days)
• Time to treatment = neurological outcome

Laboratory Studies

Essential Tests:

• CBC, CMP, LFTs (baseline, nutritional status)
• Calcium (hypercalcemia common in bone mets)
• Tumor markers (PSA, CEA, CA 19-9, AFP)
• SPEP/UPEP (exclude myeloma)
• HIV (if unknown primary)

Imaging

Biopsy

Indications:

• Unknown primary
• Solitary lesion (exclude primary tumor)
• Atypical imaging features
• No other accessible biopsy site

Differential Diagnosis

A destructive or marrow-replacing vertebral lesion is not always a carcinoma metastasis. The key differentials and discriminating features are:

View larger

Algorithm

View larger

Corticosteroid Protocol

Dexamethasone for MESCC:

Mechanism: Reduces vasogenic edema, possible tumoricidal effect on lymphoma. Co-prescribe gastric protection and monitor glucose; taper once definitive treatment is established.

Bone-Modifying Agents

Every patient with solid-tumour bone metastases (and myeloma) should be considered for a bone-modifying agent to reduce skeletal-related events (SREs: pathological fracture, cord compression, need for radiotherapy or surgery to bone, and hypercalcaemia):

• Bisphosphonates (zoledronic acid) - inhibit osteoclast-mediated resorption; reduce SREs across solid tumours and myeloma; renally cleared, so avoid or dose-reduce in renal impairment.
• Denosumab - a monoclonal RANKL inhibitor, at least as effective as zoledronic acid for SRE reduction, given subcutaneously and not renally cleared, but its effect is reversible.
• Both require a dental review before starting and calcium plus vitamin D supplementation.

Non-Operative Management

Indications:

• SINS 0-6 (stable)
• Bilsky 0-1b with radiosensitive tumor
• Poor surgical candidate (ECOG 3-4)
• Life expectancy under 3 months

Surgical Management

Surgical Complications

Radiation Complications

Disease Progression

Local Recurrence:

• cEBRT alone (radioresistant): 30-40% at 1 year
• SBRT: 5-15% at 1 year
• Separation surgery + SBRT: 5-10% at 1 year

Global Epidemiology

Spine is the most common site of skeletal metastasis worldwide, and the spine is involved in the majority of patients with bone metastases at autopsy. Roughly 10-30% of cancer patients develop clinically relevant spinal metastases during their disease, and around 5-10% develop metastatic epidural spinal cord compression (MESCC). As cancer survival improves globally with modern systemic therapy, the population living with spinal metastases is growing, increasing demand for spine oncology services. Across high-income health systems the dominant primaries are consistent: in the SCORAD cohort (UK and Australia) prostate (44%), lung (19%) and breast (12%) accounted for most MSCC, mirroring the BPLTK pattern (Hoskin, JAMA 2019, PMID 31794625).

Side-by-Side Guidance

Registry and Trial Evidence

There is no single dominant international spinal-metastasis registry equivalent to arthroplasty registries; the evidence base rests on landmark RCTs (Patchell 2005, SCORAD 2019, RTOG 0631 2023) plus large institutional cohorts (e.g. the Laufer separation-surgery series) and prospective prognostic-score validation (Tokuhashi, Tomita). The Global Spine Tumour Study Group and AO Spine Knowledge Forum Tumour have driven prospective multinational data collection on surgical outcomes, quality of life and prognostic modelling, increasingly favouring patient-reported outcomes over survival alone.

Practice Variation

Real-world practice varies with access to technology and multidisciplinary infrastructure. SBRT/SRS and separation surgery are concentrated in tertiary centres with image-guided radiotherapy and spinal navigation; in lower-resource settings conventional EBRT and posterior decompression-stabilisation remain the mainstay. Timeliness also varies: NICE-style emergency pathways with 24-hour MRI access are not universally available, and delayed diagnosis remains a major determinant of poorer ambulatory outcome globally.

Metastatic spine disease affects 10-30% of cancer patients, with 70% occurring in the thoracic spine due to red marrow distribution. The SINS score (6 components: location, pain, lesion type, alignment, vertebral body collapse, posterolateral involvement) determines mechanical stability—scores ≥13 require surgical stabilization. The NOMS framework integrates Neurologic (Bilsky grading), Oncologic (radiosensitivity), Mechanical (SINS), and Systemic factors for treatment decisions. BPLTK primaries (Breast, Prostate, Lung, Thyroid, Kidney) account for 80% of cases. Radioresistant tumors (RCC, thyroid, melanoma) require separation surgery with SBRT rather than conventional radiation for durable local control.

1. Fisher CG, DiPaola CP, Ryken TC, et al. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010;35(22):E1221-9. PMID 20562730. doi:10.1097/BRS.0b013e3181e16ae2
2. Fourney DR, Frangou EM, Ryken TC, et al. Spinal instability neoplastic score: an analysis of reliability and validity from the Spine Oncology Study Group. J Clin Oncol. 2011;29(22):3072-7. PMID 21709187. doi:10.1200/JCO.2010.34.3897
3. Bilsky MH, Laufer I, Fourney DR, et al. Reliability analysis of the epidural spinal cord compression scale. J Neurosurg Spine. 2010;13(3):324-8. PMID 20809724. doi:10.3171/2010.3.SPINE09459
4. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet. 2005;366(9486):643-8. PMID 16112300. doi:10.1016/S0140-6736(05)66954-1
5. Laufer I, Iorgulescu JB, Chapman T, et al. Local disease control for spinal metastases following "separation surgery" and adjuvant hypofractionated or high-dose single-fraction stereotactic radiosurgery. J Neurosurg Spine. 2013;18(3):207-14. PMID 23339593. doi:10.3171/2012.11.SPINE12111
6. Ryu S, Deshmukh S, Timmerman RD, et al. Stereotactic radiosurgery vs conventional radiotherapy for localized vertebral metastases of the spine: phase 3 results of NRG Oncology/RTOG 0631 randomized clinical trial. JAMA Oncol. 2023;9(6):800-7. PMID 37079324. doi:10.1001/jamaoncol.2023.0356
7. Hoskin PJ, Hopkins K, Misra V, et al. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer: the SCORAD randomized clinical trial. JAMA. 2019;322(21):2084-94. PMID 31794625. doi:10.1001/jama.2019.17913
8. Barzilai O, Laufer I, Yamada Y, et al. Integrating evidence-based medicine for treatment of spinal metastases into a decision framework: neurologic, oncologic, mechanical stability, and systemic disease. J Clin Oncol. 2017;35(21):2419-27. PMID 28640703. doi:10.1200/JCO.2017.72.7362
9. Tomita K, Kawahara N, Kobayashi T, et al. Surgical strategy for spinal metastases. Spine (Phila Pa 1976). 2001;26(3):298-306. PMID 11224867. doi:10.1097/00007632-200102010-00016
10. Tokuhashi Y, Matsuzaki H, Oda H, et al. A revised scoring system for preoperative evaluation of metastatic spine tumor prognosis. Spine (Phila Pa 1976). 2005;30(19):2186-91. PMID 16205345. doi:10.1097/01.brs.0000180401.06919.a5